MetaCap

Kyntra Bio (KYNB) vs MetaVia (MTVA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MetaVia is the larger company by market cap ($6.8 million vs $6.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KYNB-74.55%MTVA-30.82%
+15%-32%-79%
Oct 7, 20261 yearNov 20, 2026
KYNB-74.47%MTVA-28.37%
+5%-37%-78%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KYNB versus MTVA key metrics
MetricKYNBMTVA
Share price$1.56$1.01
Market cap$6.32M$6.81M
1-day change-13.33%-7.34%
YTD return-82.23%—
1-year return-81.47%—
5-year return-99.49%—
EPS (TTM)$-4.35$-2.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.44M—
Revenue growth (YoY)-78.26%—
Net income (latest FY)$183.45M$-12.97M
Gross margin91.37%—
Operating margin-712.66%—
Net margin2848.63%—
52-week high$10.47$13.42
52-week low$1.56$0.966
Distance from 52-week high-85.10%-92.47%
Analyst consensusnonenone
Avg. price target upside+2442.95%+1813.86%
Average volume29.96K113.44K
Shares outstanding4.05M6.74M
Employees348
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Kyntra Bio

KYNB stock →

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees

About MetaVia

MTVA stock →

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

KYNB vs MTVA FAQ

Which is bigger, Kyntra Bio or MetaVia?

MetaVia (MTVA) is larger, with a market capitalization of $6.81M compared with $6.32M for Kyntra Bio (KYNB).

Are Kyntra Bio and MetaVia in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons